DNTH vs. MLYS, WVE, ANAB, NRIX, NUVB, BCYC, SVRA, IRON, PAHC, and AUPH
Should you be buying Dianthus Therapeutics stock or one of its competitors? The main competitors of Dianthus Therapeutics include Mineralys Therapeutics (MLYS), Wave Life Sciences (WVE), AnaptysBio (ANAB), Nurix Therapeutics (NRIX), Nuvation Bio (NUVB), Bicycle Therapeutics (BCYC), Savara (SVRA), Disc Medicine (IRON), Phibro Animal Health (PAHC), and Aurinia Pharmaceuticals (AUPH). These companies are all part of the "pharmaceutical preparations" industry.
Mineralys Therapeutics (NASDAQ:MLYS) and Dianthus Therapeutics (NASDAQ:DNTH) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, community ranking, valuation, earnings, risk, dividends, institutional ownership, media sentiment and profitability.
Mineralys Therapeutics' return on equity of -20.82% beat Dianthus Therapeutics' return on equity.
Mineralys Therapeutics has a beta of 2.05, indicating that its stock price is 105% more volatile than the S&P 500. Comparatively, Dianthus Therapeutics has a beta of 1.77, indicating that its stock price is 77% more volatile than the S&P 500.
Dianthus Therapeutics has higher revenue and earnings than Mineralys Therapeutics. Mineralys Therapeutics is trading at a lower price-to-earnings ratio than Dianthus Therapeutics, indicating that it is currently the more affordable of the two stocks.
Mineralys Therapeutics and Dianthus Therapeutics both received 10 outperform votes by MarketBeat users.
Mineralys Therapeutics presently has a consensus target price of $33.50, indicating a potential upside of 154.75%. Dianthus Therapeutics has a consensus target price of $43.40, indicating a potential upside of 56.74%. Given Dianthus Therapeutics' higher probable upside, equities research analysts plainly believe Mineralys Therapeutics is more favorable than Dianthus Therapeutics.
84.5% of Mineralys Therapeutics shares are held by institutional investors. Comparatively, 47.5% of Dianthus Therapeutics shares are held by institutional investors. 33.2% of Mineralys Therapeutics shares are held by company insiders. Comparatively, 16.6% of Dianthus Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
In the previous week, Dianthus Therapeutics had 2 more articles in the media than Mineralys Therapeutics. MarketBeat recorded 12 mentions for Dianthus Therapeutics and 10 mentions for Mineralys Therapeutics. Dianthus Therapeutics' average media sentiment score of 0.21 beat Mineralys Therapeutics' score of 0.07 indicating that Mineralys Therapeutics is being referred to more favorably in the media.
Summary
Dianthus Therapeutics beats Mineralys Therapeutics on 7 of the 13 factors compared between the two stocks.
Get Dianthus Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for DNTH and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding DNTH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Dianthus Therapeutics Competitors List
Related Companies and Tools
